Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Adding Trastuzumab to Standard Chemotherapy in Patients With Advanced HER2-negative Gastric Cancer and HER2 Positive Expression in Circulating Tumor Cells

NCT04168931 is registered in ClinicalTrials.gov with AC Camargo Cancer Center as lead sponsor.

NCT NCT04168931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04168931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Adding Trastuzumab to Standard Chemotherapy in Patients With Advanced HER2-negative Gastric Cancer and HER2 Positive Expression in Circulating Tumor Cells
Lead sponsor
AC Camargo Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
January 1, 2020
Completion date
January 13, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iv